Get the latest on Cellectar Biosciences' Q3 2025 earnings, EMA progress for iopofosine, clinical pipeline updates, and strategic outlook.

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.

The latest round of country climate plans ‘barely move the needle’ on future warming, the head of the UN Environment ...

The options market for options on American Airlines ($AAL) stock has been turbulent as the airline presents a mixed picture ...

Large financial institutions that engage in regulatory arbitrage by exploiting regulatory frameworks across jurisdictions to minimise regulatory burdens may reduce costs but may also increase risks ...

In the short run, when firms cannot reassign labor, change suppliers, or adjust technologies, output losses ripple through every downstream stage of production. A shortage of a single key input can ...

Luke List's third round unraveled spectacularly on his sixth hole of the day at Mexico's El Cardonal at Diamante ...

Thaler says you should be especially wary when you're in auctions or bidding wars with lots of people. If you're the winner ...

The High Court has looked at whether the obligation to pay for shares under a put option was conditional on certain documentation being provided ...